Anti-MerTK (Tyr749/753/754) Antibody

Name: Anti-MerTK (Tyr749/753/754) Antibody
Brand: PhosphoSolutions
SKU: p186-749
Price: 415.0 USD
Availability: InStock

from PhosphoSolutions Datasheet Trial Size Pooled Serum

21 Citations

Our Anti-MerTK (Tyr749/753/754) rabbit polyclonal phosphospecific primary antibody from PhosphoSolutions is produced in-house. It detects human, mouse, and rat MerTK Tyr749/753/754 and is antigen affinity purified from pooled serum. It is great for use in WB.

Product Type

Primary Antibody

Species Reactivity

Human, Mouse, Rat

Expected Reactivity

Bovine, Canine, Chicken, Finch, Guinea Pig, Non-Human Primate

Applications

Host Species

Rabbit

Format

Antigen Affinity Purified from Pooled Serum

Gene Name

MERTK

Molecular Weight

160 kDa

Go to Full Product Details

Western blot of HEK293 lysate showing specific immunolabeling of the ~160 kDa MerTK phosphorylated at Tyr749/753/754 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase (λ-Ptase, 1200 units for 60 minutes).

Volume: 100 µL

Variant

Price:

$415

Quantity:

Bulk Order Anti-MerTK (Tyr749/753/754) Antibody

Product Details

Target

MerTK Tyr749/753/754

Target Description

Along with Tyro-3 and Axl, Mer is a member of the TAM family of receptor tyrosine kinases (RTKs). The TAM family of RTKs regulates cell proliferation/survival, cell adhesion and migration, and blood clot stabilization processes, along with the regulation of inflammatory cytokine release (Linger et al, 2008). Additionally, the TAM family has been linked to coagulopathy and cancer when altered experimentally or genetically (Linger et al, 2008). Tri-phosphorylation of MerTK at tyr749, tyr753 and tyr754 has been identified as a key target in platelet aggregation for developing a new anti-platelet drug that decreases bleeding complications, which are current side effects of similar drugs on the market today (Zhang et al, 2013). MerTK is also seen as a therapeutic target for treating lymphoblastic leukemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine and brain cancers (Graham et al, 1994). There has recently been increased interest in synthesizing novel ATP-competitive small molecule tyrosine kinase inhibitors to decrease tri-phosphorylation of MerTK at tyr749, tyr753, and tyr754 as a therapeutic target to treat AML (Lee-Sherick et al, 2013).

Format

Antigen Affinity Purified from Pooled Serum

Clonality

Polyclonal

Isotype

IgG

Applications

Host Species

Rabbit

Gene Name

MERTK

Molecular Weight

160 kDa

Antigen

Synthetic phospho-peptide corresponding to amino acid residues surrounding Tyr749/753/754 of human MerTK, conjugated to keyhole limpet hemocyanin (KLH).

Species Reactivity

Human, Mouse, Rat

Expected Reactivity

Bovine, Canine, Chicken, Finch, Guinea Pig, Non-Human Primate

Antibody Registry ID

AB_2744537

Storage

Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.

Physical State

Liquid

Production Notes

Prepared from pooled rabbit serum by affinity purification via sequential chromatography on phospho and non-phosphopeptide affinity columns.

Buffer

10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.

Dilution Ranges

WB: 1:1000

Conjugate

Unconjugated

Specificity

Specific for the ~160 kDa MerTK protein phosphorylated at Tyr749/753/754. The immunolabeling is completely eliminated by treatment with λ-phosphatase. Due to post-translational modifications of the Mer protein, a significant shift in molecular weight is seen from the predicted molecular weight of 110 kDa. For optimal results immunoprecipitation is recommended due to the 91% homology of the related receptor tyrosine kinase, Axl, that runs at ~140 kDa.

Post Translational Modification Type

Phosphorylated

Post Translational Modification Residue

Tyr749,753,754

Quality Control

Western blots performed on each lot.

Usage Statement

For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.

Expiration

After date of receipt, stable for at least 1 year at -20°C.

Shipping

Blue Ice

Synonyms

c MER antibody, c mer proto oncogene tyrosine kinase antibody, c-mer antibody, cMER antibody, cmer protooncogene tyrosine kinase antibody, Eyk antibody, MER antibody, MER receptor tyrosine kinase antibody, MERK antibody, MERPEN antibody, Mertk antibody, MERTK c-mer proto-oncogene tyrosine kinase antibody, MERTK_HUMAN antibody, MGC133349 antibody, nmf12 antibody, Nyk antibody, Proto oncogene tyrosine protein kinase MER antibody, Proto oncogene tyrosine protein kinase MER precursor antibody, Proto-oncogene c-Mer antibody, Receptor tyrosine kinase MerTK antibody, RP38 antibody, STK kinase antibody, Tyrosine-protein kinase Mer antibody

UniProt Details

UniProt (Human): Q12866
UniProt (Immunogen Species): Q12866

NCBI Gene ID

10461

Product Specific References for Applications and Species

Western Blot: Human | Mouse

Western Blot: Human
PMID	Dilution	Publication
34038857	not listed	Zheng, H., et al. 2021. UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry, 220,p. 113534.
31497954	not listed	Da, C., et al. 2019. Data-driven construction of anti-tumor agents with controlled polypharmacology. Journal of the American Chemical Society, 141(39):15700-15709.
30482852	not listed	Sinik, L., et al. 2019. . Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Molecular Cancer Therapeutics, 18(2), pp.278-288.
303471555	not listed	Zhao, J., et al. 2018. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry, 61(22), pp.10242-10254.
30194074	not listed	Yan, D., et al. 2018. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members. Clinical Cancer Research, 24(24), pp.6523-6535.
30093568	not listed	McDaniel, N.K., et al. 2018. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics, 17(11), pp.2297-2308.
29045015	not listed	Branchford, B.R., et al. 2018. The small‐molecule MERTK inhibitor UNC 2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 16(2), pp.352-363.
27783662	not listed	Sufit, A., et al. 2016. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. PLoS One, 11(10):e0165107.
27649555	not listed	DeRyckere, D., et al. 2017. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research, 23(6):1481-1492.
27158668	not listed	Minson, K.A., et al. 2016. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight, 1(3):e85630.
26162689	not listed	Cummings, C.T., et al. 2015. Small molecule inhibition of MERTK is efficacious in non-smal cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics, 14(9):2014-2022.
25762638	not listed	Lee-Sherick, A.B., et al. 2015. Efficacy of a Mer and lt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget, 6(9):6722-36.
25372020	not listed	Cummings, C.T., et al. 2015. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget, 5(21):10434-45.
24219778	not listed	Zhang, W., et al. 2013. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry, 56(23), pp.9693-9700.
24195762	not listed	Zhang, W., et al. 2013. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry, 56(23), pp.9683-9692.
23997116	not listed	Christoph, S., et al. 2013. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics, 12(11):2367-77.
23693152	not listed	Liu, J., et al. 2013. UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry, 65:83-93.
23585477	not listed	Schlegel, J., et al. 2013. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 123(5):2257-67.
23474756	not listed	Lee-Sherick, A.B., et al. 2013. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene, 32(46):5359-68.
23353780	not listed	Brandao, L.N., et al. 2013. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal, 3:e101.
22890323	not listed	Linger, R., et al. 2013. Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer. Oncogene, 32(29):3420-3431.

Western Blot: Mouse
PMID	Dilution	Publication
303471555	not listed	Zhao, J., et al. 2018. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry, 61(22), pp.10242-10254.
29045015	not listed	Branchford,B.R., et al. 2017. The small‐molecule MERTK inhibitor UNC 2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 16(2), pp.352-363.
25068800	not listed	Zhang, W, et al. 2014. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry, 57(16), pp.7031-7041.
24219778	not listed	Zhang, W, et al. 2013. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry, 56(23), pp.9693-9700.
24195762	not listed	Zhang, W, et al. 2013. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry, 56(23), pp.9683-9692.

Recover password

Create my account

Anti-MerTK (Tyr749/753/754) Antibody

Our Anti-MerTK (Tyr749/753/754) rabbit polyclonal phosphospecific primary antibody from PhosphoSolutions is produced in-house. It detects human, mouse, and rat MerTK Tyr749/753/754 and is antigen affinity purified from pooled serum. It is great for use in WB.